Becton, Dickinson and Company (BDX) stock analysis

Healthcare · Medical Instruments & Supplies

From the 10-K filed 2025-11-25

Business type: Franchise

How it makes money

It generated $21.840 billion in 2025, driven by Medication Management sales of infusion pumps and dedicated disposables used across hospital and clinical settings.

Revenue is concentrated in the Medical segment, which provides critical hardware for medication delivery and management. Profitability relies on the continuous pull through of high-volume 'dedicated disposables' like catheters and syringes used with its installed base of Alaris infusion systems.

The Pharmaceutical Systems unit provides a layer of stable, recurring income by supplying prefillable syringes directly to pharmaceutical companies. These systems act as the primary container for injectable drugs, essentially becoming a drug/device combination product.

What growth costs

It spent $3.914 billion to acquire Edwards Lifesciences’ Critical Care group, adding AI-enabled clinical monitoring to its intensive care and operating room portfolio.

Growth is pursued through strategic acquisitions in faster-growing market segments. The $3.914 billion acquisition of the Advanced Patient Monitoring unit integrates AI-driven clinical decision tools into its existing acute care portfolio.

The company is also undergoing a major structural reorganization into five segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional, and Life Sciences. This entails streamlining factory productivity through its 'BD Excellence' program and investing in enterprise-wide renewable energy strategy.

What could damage it

Failure to resolve the Alaris pump Consent Decree could trigger an FDA order to cease manufacturing, with potential fines of $15 million per year.

The company operates under a longstanding FDA Consent Decree regarding its infusion pumps. The FDA has the authority to order a complete cessation of manufacturing and distribution if it finds quality system violations.

Additional risk comes from increasing regulation of ethylene oxide, the primary sterilant for its medical devices. New EPA standards could force temporary facility suspensions or permanent operational limits, potentially halting the production of critical medical supplies.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

More on BDX

Other companies in Medical Instruments & Supplies